Keep Moving
Enhancing Daily Wellness
Our specially crafted blend includes 2000 mg of various components, featuring CBDA, aimed at enriching your daily wellness practices. This blend incorporates elements like Alpha-Pinene, Beta-caryophyllene, and Bisabol terpenes, selected for their characteristics that are considered to be beneficial for wellness. These components work together to create a formula intended to augment your everyday activities.
2000mg per bottle
(1000mg CBDA + 500mg CBD + 500mg CBG)
Smaller Dose, Greater Impact
0.25ml = 8mg CBDA + 4mg CBD + 4mg CBG
*Also available in a convenient mini size.
scroll to learn more
Our team of experts has carefully crafted this tincture to offer support in addressing life's challenges. It contains CBD (cannabidiol), CBG (cannabigerol), and CBDA (the precursor to cannabidiol), which are known for their researched properties. CBG is particularly relevant for addressing discomfort related to nerves, and it has also been explored for its potential benefits in promoting digestive wellness. This makes it a preferred choice for individuals focusing on gut health.
Our formula contains CBDA, a compound that some studies suggest to have improved absorption by the body. This could mean that you need less of it to feel the benefits. However, more research is required to verify how well CBDA works in our bodies. Our formula also has three terpenes derived from natural sources: Alpha-pinene (from Rosemary), Beta-caryophyllene (from black pepper), and Bisabolol (from chamomile). The results of these compounds can differ a lot depending on the person and the situation. Please remember that this information is not medical advice or health claims. You should always ask a medical-healthcare professional if you have any questions or concerns.
Sources https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5922297/ https://pubmed.ncbi.nlm.nih.gov/31881765/ https://dmd.aspetjournals.org/content/36/9/1917.long •R Mechoulam et al. Hashish. IV. The isolation and structure of cannabinolic cannabidiolic and cannabigerolic acids. Tetrahedron 1965 May;21(5):1223-9 •Borrelli, Francesca, et al. Biochemical pharmacology 85.9 (2013): 1306-1316. •Formukong, E. A., A. T. Evans, and F. J. Evans. Inflammation 12.4 (1988): 361-371. •Pellesi, L., et al. European Journal of Clinical Pharmacology 74.11 (2018): 1427-1436. https://pubmed.ncbi.nlm.nih.gov/20157878/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6920849/ https://pubmed.ncbi.nlm.nih.gov/23138934/ https://pubmed.ncbi.nlm.nih.gov/26119957/ https://pubmed.ncbi.nlm.nih.gov/30864870/